The 4 most recent market catalysts affecting $IMTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 75
Immatics Announces Third Quarter 2026 Financial Results
Immatics announced its Q3 2026 financial results, revealing a significant increase in its net loss to $86.3 million from $57.3 million in the prior year. This widening loss is dire…
Oct 24, 2026
Corporate Catalyst
Bullish
Impact 75
Immatics Presents Clinical Activity of IMA402 and IMA203CD8 at ESMO 2026
Immatics (IMTX) announced compelling clinical data for its PRAME-targeting bispecific IMA402, demonstrating a 32% cORR, 12.5 months median DOR, and 91% 1-year OS in advanced melano…
Oct 14, 2026
Corporate Catalyst
Neutral
Impact 65
Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
Stifel's initiation of coverage on Immatics with a 'Buy' rating and a $15 price target is a positive development for the company. Analyst coverage, especially with a 'Buy' recommen…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Immatics shares are trading higher after the company announced a $150 million offering.
The $150 million offering by Immatics is a significant corporate catalyst, providing substantial capital for the company's operations, likely focusing on advancing its clinical pip…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.